


Ask a doctor about a prescription for PARICALCITOL ACCORDPHARMA 5 micrograms/ml INJECTABLE SOLUTION
Package Leaflet: Information for the User
Paricalcitol Accordpharma 5 micrograms/ml solution for injectionEFG
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the pack
Paricalcitol Accordpharma is a synthetic analogue of activated vitamin D, which is required for the normal functioning of many tissues in the body, including the parathyroid gland and bones. In people with normal kidney function, this active form of vitamin D is produced naturally by the kidneys, but in renal failure, the production of active vitamin D is significantly reduced. Therefore, paricalcitol provides a source of active vitamin D when the body cannot produce enough and helps to prevent the consequences of low levels of active vitamin D in patients with chronic kidney disease, specifically with high levels of parathyroid hormone that can cause bone problems. Paricalcitol is indicated in adult patients with chronic kidney disease stage 5.
Do not use Paricalcitol Accordpharma:
Your doctor will monitor your blood levels and will be able to tell you if these conditions apply to you.
Warnings and precautions
Talk to your doctor or nurse before you start using Paricalcitol Accordpharma.
Using Paricalcitol Accordpharma with other medicines
Tell your doctor, nurse, or pharmacist if you are using, have recently used, or might use any other medicines.
Some medicines may affect the action of paricalcitol or increase the likelihood of side effects. It is particularly important that you tell your doctor if you are using any of the following medicines:
Talk to your doctor, nurse, or pharmacist before taking any medicine.
Using Paricalcitol Accordpharma with food and drinks
Paricalcitol can be administered with or without food.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.
It is not known if this medicine is safe for pregnant or breast-feeding women. Therefore, it should only be used after consulting with your doctor, who will help you make the best decision for you.
It is not known if paricalcitol passes into human breast milk. Tell your doctor before breast-feeding while using Paricalcitol Accordpharma.
Driving and using machines
During treatment with paricalcitol, your ability to drive safely or use heavy machinery may be affected.
Paricalcitol may make you feel dizzy, weak, and/or sleepy.
Do not drive or use machines if you have these symptoms.
Important information about some of the ingredients of Paricalcitol Accordpharma
This medicine contains 157.8 mg of alcohol (ethanol) in each ml (which is equivalent to 20% v/v).
At the maximum dose of 40 mg:
It is unlikely that the amount of alcohol in this medicine will have any noticeable effect on adults or adolescents. It may have some effects on small children, such as drowsiness.
The amount of alcohol in this medicine may alter the effect of other medicines. Talk to your doctor or pharmacist if you are taking other medicines.
If you are pregnant or breast-feeding, talk to your doctor or pharmacist before you are given this medicine. This medicine is harmful to people with alcoholism.
If you have alcohol dependence, talk to your doctor or pharmacist before you are given this medicine.
Your doctor will use the results of laboratory tests to decide the initial dose suitable for you. Once you have started treatment with paricalcitol, the dose must be adjusted based on the results of routine laboratory tests. Using the results of your tests, your doctor will help you determine the dose of this medicine suitable for you.
Paricalcitol will be administered by your doctor or nurse while you are being treated with the kidney machine. It will be administered through the tube that connects you to the machine. You will not need to receive an injection, as this medicine can be introduced directly into the tube being used for your treatment. You will not receive paricalcitol more frequently than every other day and no more than 3 times a week.
If you use more Paricalcitol Accordpharma than you should
An overdose of paricalcitol may produce abnormally high levels of calcium in the blood, which can be harmful. The symptoms that may appear soon after taking too much paricalcitol may include:
If you experience high levels of calcium in the blood after using paricalcitol, your doctor will prescribe the appropriate treatment to return to normal calcium levels. Once your calcium levels return to normal, it is likely that you will be given low doses of this medicine.
Your doctor will monitor your blood levels. If you experience any of the symptoms mentioned above, seek medical advice immediately.
The symptoms that may appear after a long period of receiving too much paricalcitol are:
If you experience high levels of calcium in the blood after using paricalcitol, your doctor will prescribe the appropriate treatment to return to normal calcium levels. Once your calcium levels return to normal, it is likely that you will be given low doses of this medicine.
In case of overdose or accidental ingestion, go immediately to a medical center or call the Toxicology Information Service, phone 91 562 04 20, indicating the medicine and the amount ingested.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Several allergic reactions have been reported with Paricalcitol Accordpharma. Important: if you notice any of the following side effects, tell your doctor or nurse immediately:
Tell your doctor or nurse if you notice any of the following side effects:
Common (may affect up to 1 in 10 people) are:
Uncommon (may affect up to 1 in 100 people) are:
Frequency not known(cannot be estimated from the available data):
If you notice these symptoms, seek medical help immediately.
You may not identify these side effects unless your doctor has previously informed you.
If you think any of the side effects you are experiencing are serious or if you notice any side effects not mentioned in this leaflet, tell your doctor, nurse, or pharmacist immediately.
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if they are not listed in this leaflet. You can also report side effects directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Store the ampoules in the outer packaging to protect from light.
Paricalcitol Accordpharma should be used immediately after opening.
Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date is the last day of the month shown.
Do not use this medicine if you notice particles or discoloration.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of Paricalcitol Accordpharma
Appearance of the product and container contents
Paricalcitol Accordpharma is a clear and colorless aqueous solution, free of visible particles. It is presented in packs with 5 ampoules of 1 ml.
Marketing authorization holder and manufacturer
Marketing authorization holder
Accord Healthcare S.L.U.
World Trade Center. Moll de Barcelona, s/n, Edifici Est, 6ª planta.
08039, Barcelona (Spain)
Manufacturer
Pharmaten, S.A
Dervenakion 6
15351 Pallini Attiki
GRECIA
Date of the last revision of thisleaflet:June 2023
Detailed and updated information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
<------------------------------------------------------------------------------------------------------------------------- >
This information is intended only for healthcare professionals:
Instructions for the healthcare professional
Paricalcitol Accordpharma 5 micrograms/ml solution for injection
Preparation for solution for injection
Paricalcitol Accordpharma 5 micrograms/ml solution for injection is for single use. As with other parenteral medicines, the solution should be inspected for particles and discoloration before administration.
Compatibility
This medicinal product must not be mixed with other medicinal products.
Storage and shelf-life
Parenteral products should be inspected for visible particles and discoloration before administration. The solution is clear and colorless.
Store the ampoules in the outer packaging to protect from light.
This medicinal product has a shelf-life of 2 years.
Posology and method of administration
Paricalcitol Accordpharma solution for injection is administered through the hemodialysis access.
Adults
The initial dose of paricalcitol is based on the following formula:
Initial dose (micrograms) = | basal intact PTH level in pmol/l |
8 |
or
and administered as an intravenous bolus dose, with a maximum frequency of every other day and at any time during dialysis. The maximum dose administered safely in clinical studies was 40 micrograms. 2) Dose adjustment The currently accepted levels for the range of PTH in patients with end-stage renal disease undergoing dialysis are not more than 1.5 to 3 times the upper limit of normal non-uremic, 15.9 to 31.8 pmol/l (150-300 pg/ml), for intact PTH. To achieve adequate levels of physiological variables, monitoring and individualized dose adjustment are necessary. If hypercalcemia or an elevated corrected Ca x P product, greater than 5.2 mmol2/l2 (65 mg2/dl2), is observed, the dose should be reduced or interrupted until these parameters normalize. Then, the administration of paricalcitol should be restarted at a lower dose. A dose reduction may be necessary when PTH levels decrease in response to therapy. The following table is suggested as a guide for dose adjustment: | ||||
Suggested dose guide (dose adjustment at 2 to 4 week intervals) | |
PTH level in relation to the basal level | Paricalcitol dose adjustment |
Equal to or greater than | Increase by 2 to 4 micrograms |
Decrease < 30% | |
Decrease = 30% and = 60% | Maintain |
Decrease > 60% | Decrease by 2 to 4 micrograms |
PTH level < 15.9 pmol/l (150 pg/mL) |
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for PARICALCITOL ACCORDPHARMA 5 micrograms/ml INJECTABLE SOLUTION – subject to medical assessment and local rules.